Exhibit 107

Calculation of Filing Fee Tables

Form S-1

(Form Type)

Enveric Biosciences, Inc.

(Exact Name of Each Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type		Security Class Title		Fee Calculation or Carry Forward Rule		Amount Registered				Proposed Maximum Offering Price Per Unit				Maximum Aggregate Offering Price⁽¹⁾				Fee Rate				Amount of Registration Fee
Equity		Common Stock, par value $0.01 per share (“Common Stock”)⁽²⁾		457(o)										$	5,000,000				0.00015310			$	765.50
Other		Pre-funded Warrants to purchase Common Stock⁽³⁾		Other											-									⁽³⁾
Equity		Common Stock underlying the Pre-Funded Warrant⁽³⁾		457(o)											-									⁽³⁾
Other		Series A Warrants to purchase Common Stock		Other											-									⁽⁴⁾
Equity		Common Stock underlying the Series A Warrants to purchase Common Stock		457(o)										$	5,000,000				0.00015310			$	765.50
Other		Series B Warrants to purchase Common Stock		Other
Equity		Common Stock underlying the Series B Warrants to purchase Common Stock		457(o)										$	5,000,000				0.00015310			$	765.50
Other		Placement Agent Warrants to purchase Common Stock		Other											-									⁽⁴⁾⁽⁵⁾
Equity		Common Stock underlying the Placement Agent Warrants to purchase Common Stock		457(o)										$	437,500				0.00015310			$	67.00

Total Offering Amounts														$	15,437,500				0.00015310			$	2,363.50
Total Fees Previously Paid																						$	1,598.00
Total Fee Offsets																							-
Net Fee Due																						$	765.50

(1)	Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).

(2)	Pursuant to Rule 416 under the Securities Act, this registration statement shall also cover any additional shares of the registrant’s securities that become issuable by reason of any share splits, share dividends or similar transactions.

(3)	The proposed maximum aggregate offering price of the Common Stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $5,000,000.

(4)	No separate registration fee is payable pursuant to Rule 457(g) under the Securities Act.

(5)	Represents warrants issuable to the placement agent, or its designees, to purchase a number of shares of common stock equal to 7.0% of the aggregate number of shares of common stock and pre-funded warrants being offered in this offering, at an exercise price equal to 125% of the combined public offering price per share of common stock and accompanying warrants.